Member Info for Dudio

Feels like there's been a bit of stability with the SP over the past few days. Maybe even enough for the shorters and de-rampers to p!ss off to some random mining stock?!

Is that new (today?) or from their article a few days ago? Seaking, Can you post it?

Day-traders and de-rampers will also post new posts to keep great POVs / news like this further down the list. I've spotted it a fair few times before. So let's make sure that when Trinity reposts it, it stays near the top for a while. Oh! and the best way to keep deramping idiots (I really don't mind any well informed ones) out of the picture is to NOT reply to them, no matter how tempting it might be, because any reply merely does their work for them, by keeping their post fresh and at the top!

Lovely spot Matml

Oh! GH there are a whole load of more names to add to that filter list, but those two are definitely at the top of the list! ;-)

Golf, I think you're right. Essentially journalists are most likely only going to write an article based on a press release (with photos and the likes of a human interest story). What the article in the Express the other week does show is that SNG are very likely to have a PR agency involved - just maybe not a very good one, if they can just about only get in The Express. I think any approaches from any of us, mainly just help get Synairgen on their radar, so that they are more receptive when any future press releases land on their desks. Apart from P3 results, where we'd hope that every title across the globe would pick it up!

Ok Ok guys I may write cr-p posts every so often but, I think this one more than makes up for them. I got a response from the Health reporter at the Express and sent her a reply (all below). So... I've now got a direct press contact to forward the next set of big SNG news to E.g: start of stage 3 trial or results of home trial, if she hasn't picked it up already. Result! Dudio.

Her response:
Thanks for your email. We actually ran the exact story you suggest a couple of weeks ago, giving an update on the home trial, explaining how it was hindered when cases dropped during the summer and encouraging readers to sign up if they develop symptoms. There was even a small op-ed from Synairgen's CEO, although I think this only made the early edition.

Fingers crossed there's some more news soon which I'm sure we will cover!

Best wishes,
Hanna

My reply:
Hannah,

Thanks so much for getting back to me. (I did worry that my email might have ended up in your spam folder!).
I think there’s likely to be news about their stage 3 trial starting in the next few weeks as well as the results from the home trial. So watch this space!
It does feel like everyone is excited about the vaccines as the moment, which of course they should be, but I’m not sure that they are the only solution for this ugly virus, if in fact they are as effective as they currently claim they are.

I’ll keep a look out for future articles - my dad is an avid reader! ;-)

Best

Really great points CW25. Makes so much sense. I've always thought that RM is obsessed about getting great data - it's the one thing that he always brings up ref the P2 trial. They don't want to screw up 15 years of work and jeopardise any big deal.

Wrote this (below) in a separate post. Most journalists these days don't have time to do any proper journalism. What they do need is a press release that as good as gives them their story. Things like surveys and personal stories help create the story too. And in most instances they need a photo to be central to it too. I wrote to the Express because they've run the story before and gave them an idea for a follow-up. Any PR types on here who can better advise?

Just sent this to Hannah Geissler, Health Reporter at The Express, as a follow-up to her home trials article back in October...

Hanna,

In the current climate of ‘vaccines, vaccines’ vaccines’ it appears that the potential Covid-19 ‘wonder drug’ from Synairgen that you wrote about back in October, has gone off the radar. Having recently lost a close friend and two distant family members (on the same day) to Covid-19, it’s so frustrating that it appears that the home trial that you wrote about still hasn’t been completed, due to a slow take-up.

Is this a great opportunity for The Express to rally behind this home trail to encourage more of its readers who have been unfortunate to have caught Covid-19 to sign-up? Potentially saving reader’s lives as well as helping to find a British answer to Covid-19 before we’ve benefited from any significant vaccine roll-out deep into 2021?

Kind Regards

Just sent this to Hannah Geissler, Health Reporter at The Express, as a follow-up to her home trials article back in October...

Hanna,

In the current climate of ‘vaccines, vaccines’ vaccines’ it appears that the potential Covid-19 ‘wonder drug’ from Synairgen that you wrote about back in October, has gone off the radar. Having recently lost a close friend and two distant family members (on the same day) to Covid-19, it’s so frustrating that it appears that the home trial that you wrote about still hasn’t been completed, due to a slow take-up.

Is this a great opportunity for The Express to rally behind this home trail to encourage more of its readers who have been unfortunate to have caught Covid-19 to sign-up? Potentially saving reader’s lives as well as helping to find a British answer to Covid-19 before we’ve benefited from any significant vaccine roll-out deep into 2021?

Kind Regards

Agree ShareSting, have been thinking similar. I think that these guys are in this for far more than a quick sell-off to a big Pharma. It's about seeing 15 years of hard work turning into something much bigger and making a huge mark in the world. Turning the company into a major Pharmaceutical makes a ton of sense. Even a small slice of Big Pharma would see a big mcap for them one day. (The top 20 Big Pharma have a combined MCap of $2.63 Trillion). This is a mid to long-term investment, even though day traders and shorters have been recently having their fun.

Shan. Unless there's a EUA beforehand of course.

Well said Bite. Some might have been waiting for as long as 15 years too!

Alinz, I welcome posters on here with contrarian views, but only if their posts aren't vacuous, and have at least a tiny morsel of evidence to back up their POV. However, every time I have seen a post by Pete he has failed to back up his claims. (He's one of only 3 that I've filtered, so I didn't see this morning's post). He's either lazy, an idiot, or deliberately trying to disrupt what should be an informative BB - informative for and against investing in this share.

Bargain hunter who must think that the SP won't go any / much lower!

Tommy. I think it might come earlier than Feb. EUA based on combined P2 and Home trial?

Taken from an old presentation from RM, which I'm sure is pre-Covid. He shows some examples of Big Pharma buying biotech deals that he's comparing Synairgen with. Both are fibrosis related, the second more specific to the lungs I think - so both chosen for their relevance I guess. This is what he wrote:
Phase 2 deal: Bristol Myers-Squibb enters and agreement in 2015 providing exclusive rights to acquire Promedior Inc for $1.25Billion
Post approval deal: Roche squired Intermune in 2014 for $8Bn, main programme was pirfenidone for IPF, and other anti fibrosis programmes.
In short he has no ambition of selling Synairgen for £180M or less. So, unless you're buying or have to sell to free up some cash, then the current share price is irrelevant.
Dudio.

Agree Snow. Seems like RM and SNG might be pretty confident that their orders will be snapped up, either in advance or in early 2021.

I think it's as simple as this:
Short-term down-side: we're not the first or sole answer to Covid (which put some of us in £50 SP dreamland). SP has hit a low, and could even have a bit further to fall if all we hear is vaccines, vaccines, vaccines.
Mid-term up-side: once P3 is approved, we'll be needed across the world in 2021, as global vaccination will take time.
Long-term up-side: future viruses, COPD, flu, asthma etc...

However, I wonder if we'll get a EUA in the next few weeks, once home trials and or the first half of P3 data gets included alongside the P2 data set? (with the P2 peer review to give credibility)

No one should mind certain contrarians on this BB - the ones who provide some interesting information and evidence to back up their point of view. However, I never see Rob do this. So Rob, I suggest you come back with some more detail to back up your point of view. Come on give it a go...